Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS

NCT02592434 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02592434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02592434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
June 10, 2016
Completion date
May 16, 2019
Enrollment
225 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis